US2012088744A1PendingUtilityA1
Compositions for treating cmt and related disorders
Est. expiryJun 2, 2029(~2.9 yrs left)· nominal 20-yr term from priority
A61P 25/00A61P 25/28A61K 31/567A61K 31/7004A61K 9/0053A61K 31/555A61K 31/4178A61K 31/4164A61K 31/047A61K 31/439A61K 31/436A61K 31/485A61K 31/575A61K 31/197A61K 31/195A61K 45/06A61K 31/192A61P 25/02A61K 47/00A61K 31/407
53
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.
Claims
exact text as granted — not AI-modified1 - 13 . (canceled)
14 . A composition comprising baclofen, sorbitol and a compound selected from pilocarpine, methimazole, mifepristone, naltrexone, rapamycin, flurbiprofen, ketoprofen or salts, enantiomers, racemates or prodrugs of pilocarpin, methimazole, mifepristone, naltrexone, rapamycin, flurbiprofen or ketoprofen, for simultaneous, separate or sequential administration to a mammalian subject.
15 . The composition according to claim 14 , said composition comprising naltrexone, baclofen and D-sorbitol.
16 . The composition according to claim 14 , said composition, further comprising a pharmaceutically suitable excipient or carrier.
17 . The composition according to claim 14 , wherein said compounds are formulated with a drug eluting polymer, a biomolecule, a micelle or liposome-forming lipids or oil in water emulsions, or pegylated or solid nanoparticles or microparticles for oral or parenteral or intrathecal administration.
18 . A composition comprising:
(a) rapamycin, (b) mifepristone or naltrexone, and (c) a compound selected from pilocarpin, methimazole and baclofen, for simultaneous, separate or sequential administration to a mammalian subject.
19 . The composition according to claim 18 , said composition comprising:
(a) rapamycin, (b) mifepristone, and (c) a compound selected from pilocarpin, methimazole or baclofen, for simultaneous, separate or sequential administration to a mammalian subject.
20 . The composition according to claim 18 , said composition comprising rapamycin, mifepristone and pilocarpin.
21 . The composition according to claim 18 , said composition comprising rapamycin, mifepristone and baclofen.
22 . The composition according to claim 18 , said composition comprising rapamycin, mifepristone and methimazole.
23 . The composition according to claim 18 , said composition comprising rapamycin, naltrexone and methimazole.
24 . The composition according to claim 18 , said composition, further comprising a pharmaceutically suitable excipient or carrier.
25 . The composition according to claim 18 , wherein said compounds are formulated with a drug eluting polymer, a biomolecule, a micelle or liposome-forming lipids or oil in water emulsions, or pegylated or solid nanoparticles or microparticles for oral or parenteral or intrathecal administration.
26 . A method of treating Charcot-Marie-Tooth (CMT) disease or a related disorder comprising the administration of an effective amount of a composition according to claim 14 to a subject having CMT or a related disorder.
27 . The method according to claim 26 , wherein said related disorder is toxic neuropathy or amyotrophic lateral sclerosis (ALS).
28 . A method of treating Charcot-Marie-Tooth (CMT) disease or a related disorder comprising the administration of an effective amount of a composition according to claim 16 to a subject having CMT or a related disorder.
29 . The method according to claim 28 , wherein said related disorder is toxic neuropathy or amyotrophic lateral sclerosis (ALS).Join the waitlist — get patent alerts
Track US2012088744A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.